Intravenous antibiotics reduce the presence of Aspergillus in adult cystic fibrosis sputum

Thorax. 2013 Jul;68(7):652-7. doi: 10.1136/thoraxjnl-2012-202412. Epub 2013 Mar 19.

Abstract

Background: Pseudomonas aeruginosa and Aspergillus fumigatus frequently co-colonise the airways of patients with cystic fibrosis (CF). This study aimed to assess the impact of short-term administration of intravenous antipseudomonal antibiotics during CF exacerbations on the presence of Aspergillus.

Methods: Pre- and post-antibiotic sputum samples from 26 adult patients with CF and chronic Pseudomonas colonisation were analysed for the presence of Aspergillus by fungal culture, real-time PCR and galactomannan antigen (GM). Lung function (forced expiratory volume in 1 s and forced vital capacity % predicted) and blood levels of total IgE, specific A fumigatus IgE and specific A fumigatus IgG were measured at the start and end of antibiotics. Respiratory viral real-time PCR and bacterial community profiling using ribosomal intergenic spacer analysis (RISA) were performed to estimate concurrent changes in the lung microbiome.

Results: Aspergillus PCR and GM were more sensitive than culture in detecting Aspergillus species (culture 8%, GM 31%, PCR 77%). There was a significant decline in the presence of Aspergillus, measured both by PCR and GM index, following antibacterial therapy (PCR: median increase in crossing threshold 1.7 (IQR 0.5-3.8), p<0.001; GM: median fall in GM index 0.7 (IQR 0.4-1.6), p=0.016). All patients improved clinically with a significant increase in lung function (p<0.0001). RISA community analysis showed large changes in bacterial community similarity in 67% of patients following antibiotics. Viral RT-PCR demonstrated the presence of a concurrent respiratory virus in 27% of patients.

Conclusions: Intravenous antibiotics targeting Pseudomonas during CF pulmonary exacerbations have a negative impact on the presence of Aspergillus in sputum samples.

Keywords: Aspergillus Lung Disease; Cystic Fibrosis; Respiratory Infection.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Bacterial Agents / administration & dosage*
  • Antibodies, Fungal / analysis
  • Aspergillosis / diagnosis
  • Aspergillosis / drug therapy*
  • Aspergillosis / microbiology
  • Aspergillus fumigatus / genetics
  • Aspergillus fumigatus / immunology
  • Aspergillus fumigatus / isolation & purification*
  • Cystic Fibrosis / complications
  • Cystic Fibrosis / microbiology*
  • Cystic Fibrosis / physiopathology
  • DNA, Fungal / analysis
  • Female
  • Follow-Up Studies
  • Forced Expiratory Volume
  • Humans
  • Injections, Intravenous
  • Male
  • Prospective Studies
  • Pseudomonas Infections / diagnosis
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / microbiology
  • Real-Time Polymerase Chain Reaction
  • Sputum / microbiology*
  • Treatment Outcome
  • Vital Capacity

Substances

  • Anti-Bacterial Agents
  • Antibodies, Fungal
  • DNA, Fungal